Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells

International Journal of Cancer

Volumn 120, Issue 9, 2007, Pages 1891-1898

  Zhang, Xiaomeng ^a   Wang, Qi ^a   Ling, Ming Tat ^a   Wong, Yong Chuan ^a   Leung, Steve C L ^a   Wang, Xianghong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Akt; Cancer; Resistance; Taxol; TWIST

Indexed keywords

CASPASE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR TWIST;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROTECTION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NASOPHARYNGEAL NEOPLASMS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; TWIST TRANSCRIPTION FACTOR; VINCRISTINE;

EID: 33947234746     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22489     Document Type: Article

References (31)

1. Hebrok M, Wertz K, Fuchtbauer EM. M-twist is an inhibitor of muscle differentiation. Dev Biol 1994;165:537-44.
2. Chen ZF, Behringer RR. twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 1995;9:686-99.
3. Spicer DB, Rhee J, Cheung WL, Lassar AB. Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 1996;272:1476-80.
4. Ghouzzi V, Le MM, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997;15:42-6.
5. Yousfi M, Lasmoles F, E1 GV, Marie PJ. Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFα expression and caspase-2 activation. Hum Mol Genet 2002;11:359-69.
6. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Invest 2001;107:1153-61.
7. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17.
8. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-91.
9. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82.
10. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M, Ogawa K. Expression of twist and wnt in human breast cancer. Anticancer Res 2004;24:3851-6.
11. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005;12:488-96.
12. Mironchik Y, Winnard PT, Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van DP, Burger H, Glackin C, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005;65:10801-9.
13. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
14. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153-62.
15. Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA, Rostomily RC. TWIST is expressed in human gliomas and promotes invasion. Neoplasia 2005;7:824-37.
16. Entz-Werle N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, Oudet P, Lutz P, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer 2005;117:349-55.
17. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005;65:8142-50.
18. Doom R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R, Tensen CP. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004;64:5578-86.
19. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004;23:474-82.
20. Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, Lo KW, Jin DY, et al. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol Carcinog 2005;43:237-45.
21. Cheung HW, Jin DY, Ling MT, Wong YC, Wang Q, Tsao SW, Wang X. Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 2005;65:1450-8.
22. Zhang X, Ling MT, Wang X, Wong YC. Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 2006;118:2072-81.
23. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evil is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via P13K/AKT. Oncogene 2006;25:3565-75.
24. Coltella N, Rasola A, Nano E, Bardella C, Fassetta M, Filigheddu N, Graziani A, Comoglio PM, Di Renzo MF. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer 2006;118: 2981-90.
25. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
26. Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D. Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem 2001;276:26699-707.
27. Milne D, Kampanis P, Nicol S, Dias S, Campbell DG, Fuller-Pace F, Meek D. A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein. FEBS Lett 2004;577:270-6.
28. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002;21:1299-303.
29. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65:2532-6.
30. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P, Puisieux A. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004;6:625-30.
31. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.